(Q36729613)

15 August 2017

1 reference

title

Monitoring the safe use of clozapine: a consensus view from Victoria, Australia (English)

1 reference

15 August 2017

0 references

1

1 reference

15 August 2017

4

Christos Pantelis

1 reference

15 August 2017

Joanna Fitzsimons

2

1 reference

15 August 2017

Timothy Lambert

3

1 reference

15 August 2017

Jayashri Kulkarni

5

1 reference

15 August 2017

David Castle

6

1 reference

15 August 2017

Elizabeth W Ryan

7

1 reference

15 August 2017

Sean Jespersen

8

1 reference

15 August 2017

Pat McGorry

9

1 reference

15 August 2017

Gregor Berger

10

1 reference

15 August 2017

Bill Kuluris

11

1 reference

15 August 2017

Tom Callaly

12

1 reference

15 August 2017

Seetal Dodd

13

1 reference

15 August 2017

publication date

1 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

21

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

117-127

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200721020-00003

15 August 2017

exact match

0 references

cites work

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200721020-00003

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200721020-00003

Management of the adverse effects of clozapine

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200721020-00003

Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations

21 January 2018

1 reference

12 December 2020

Rechallenge with clozapine following leucopenia or neutropenia during previous therapy

1 reference

12 December 2020

Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis

1 reference

12 December 2020

Clozapine-induced transient white blood count disorders

1 reference

12 December 2020

G-CSF and the management of clozapine-induced agranulocytosis

1 reference

12 December 2020

Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement

1 reference

12 December 2020

High risk of eosinophilia in women treated with clozapine

1 reference

12 December 2020

Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine.

1 reference

12 December 2020

ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in co

1 reference

12 December 2020

Will routine therapeutic drug monitoring have a place in clozapine therapy?

1 reference

12 December 2020

Metabolic syndrome in patients with schizophrenia.

1 reference

12 December 2020

Eosinophilia after commencement of clozapine treatment

1 reference

12 December 2020

Physical consequences of schizophrenia and its treatment: the metabolic syndrome

1 reference

12 December 2020

The effects of novel antipsychotics on glucose and lipid levels.

1 reference

12 December 2020

Leponex--associated granulocytopenia: a review of the situation

1 reference

12 December 2020

Physical health monitoring of patients with schizophrenia

1 reference

12 December 2020

Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis

1 reference

12 December 2020

Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.

1 reference

12 December 2020

Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature

1 reference

12 December 2020

The side-effects of clozapine: a four year follow-up study

1 reference

12 December 2020

Blood dyscrasias induced by psychotropic drugs.

1 reference

12 December 2020

Clozapine-associated elevation in serum triglycerides

1 reference

12 December 2020

Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome

1 reference

12 December 2020

An alternative to interruption of treatment in recurrent clozapine-induced severe neutropenia

1 reference

12 December 2020

Hepatotoxicity of clozapine.

1 reference

12 December 2020

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

1 reference

12 December 2020

Electrocardiographic abnormalities in patients treated with clozapine

1 reference

12 December 2020

Clozapine: guidelines for clinical management

1 reference

12 December 2020

Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges

1 reference

12 December 2020

A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine

1 reference

12 December 2020

Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients

1 reference

12 December 2020

New-onset diabetes and ketoacidosis with atypical antipsychotics

1 reference

12 December 2020

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

1 reference

12 December 2020

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

1 reference

12 December 2020

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

1 reference

12 December 2020

Plasma clozapine concentrations as a predictor of clinical response: a follow-up study.

1 reference

12 December 2020

Myocarditis and cardiomyopathy associated with clozapine use in the United States

1 reference

12 December 2020

Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine

1 reference

12 December 2020

Myocarditis and cardiomyopathy associated with clozapine

1 reference

12 December 2020

The clinical use of plasma clozapine levels.

1 reference

12 December 2020

The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry

1 reference

12 December 2020

Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs

1 reference

12 December 2020

Medical comorbidity in schizophrenia.

1 reference

12 December 2020

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

1 reference

12 December 2020

Long-term pharmacokinetics of clozapine

1 reference

12 December 2020

Prevalence of diabetes mellitus in patients receiving depot neuroleptics or clozapine

1 reference

12 December 2020

Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study

1 reference

12 December 2020

Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.

1 reference

12 December 2020

Diet and Exercise Among Adults With Type 2 Diabetes: Findings from the Third National Health and Nutrition Examination Survey (NHANES III)

1 reference

12 December 2020

Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity

1 reference

12 December 2020

Agranulocytosis: incidence and risk factors

1 reference

12 December 2020

Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study

1 reference

12 December 2020

A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors

1 reference

12 December 2020

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

1 reference

12 December 2020

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.

1 reference

12 December 2020

The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype

1 reference

12 December 2020

10.2165/00023210-200721020-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1025947620

0 references

1 reference